sábado, 24 de junio de 2017

Pharma execs popularity...

Sometimes adult life sends us through a disturbing time warp. It’s much too reminiscent of high school. The cool kids’ cafeteria table (or parking lot, where I grew up) becomes the cool grown-up party at J.P. Morgan, for instance. Step into biopharma Twitter, where the snark level sometimes hits Mean Girls levels. 

But today, it’s the “best all-around” votes senior year echoed in post-high school reality. Only instead of the most popular graduating senior, these votes chose the most congenial CEOs in biopharma. 

The business-information analysts over at Owler sifted through various data streams, including its own CEO rating tool (smile, frown or in-between) to come up with a ranking of the best-liked pharma leaders. The top 10 is mostly packed with Big Pharma’s top dogs, with a couple of surprises in the mix. 

Including No. 1, Sanjay Bhatia of Laborate Pharmaceuticals, a small, privately held drugmaker in Delhi, India. His approval rating with Owler’s tool? A stunning 99 out of 100. And it’s not because he has 100 employees who all voted with a smile. Laborate has an estimated 5,180 staffers and 1,980 followers on the Owler site. 

Roche and its Genentech unit swept second and third, with Roche’s Severin Schwan in second place with a 92.9 approval rating. 
Bill Anderson at Genentech clocked an 87.7.

Switzerland-based Roche bought the share of California-based Genentech it didn’t already own back in 2009, and the Genentech side of the business has delivered some of Roche’s biggest-selling drugs in the last few years. 

AbbVie’s Richard Gonzalez comes in fourth with an 83.8 approval rating—he’s been at the helm at that company since it was spun off by Abbott Laboratories in 2013. He’s consistently among the highest-paid CEOs in the industry, and while popularity among staff isn’t among his compensation metrics, driving “employee engagement” is. 

Rounding out the top five is Shire’s Flemming Ornskov, whose most recent claim to fame is the company’s buyout of Bioverativ, the hemophilia unit spun off by Baxter last year. 

 The rest of the top 10? 
Merck’s Ken Frazier; GlaxoSmithKline’s Emma Walmsley, who’s brand-new to the Glaxo CEO post; Johnson & Johnson’s Alex Gorsky; and Bayer’s relatively new chief, Werner Baumann. Steven H. Collis, CEO of the drug distributor AmerisourceBergen, came in seventh. All of their ratings fell in the 70s. (Más)

viernes, 23 de junio de 2017

Ratón de biblioteca: La Civilización Empática / Jeremi Rifkin

"This is in marked contrast to Big Pharma 
which only invests and promotes products 
if there is profit in it. 
There were no great gains to be made 
by inventing an antidote to the Ebola virus 
because, initially, it mostly affected 
poor people and nations. 
That is now changing as the current epidemic 
threatens the advanced world."
Jeremi Rifkin
The Zero Marginal Cost Society

Jeremy Rifkin, uno de los más importantes pensadores sociales de nuestro tiempo, vuelve a las librerías con La civilización empática, su obra más ambiciosa hasta la fecha. Un trabajo de gran alcance y erudición que propone la empatía como el mejor modelo, y posiblemente el único, para las relaciones internacionales y la supervivencia global en los inicios del siglo XXI. 
Parece que el mundo jamás ha estado tan interconectado a través de los medios de comunicación, el comercio y la cultura, y tan salvajemente desgarrado por la guerra, la crisis financiera, el calentamiento global e, incluso, la migración de las enfermedades
No importa cuánto nos empeñemos en la tarea de afrontar los desafíos de un rápido mundo globalizador, la raza humana parece quedarse corta continuamente, incapaz de reunir los recursos mentales colectivos para pensar globalmente y actuar localmente .


Manual/Decálogo para entender un "millennials"

En este libro el autor expone cómo la desconexión entre nuestra visión del mundo y nuestra habilidad para percibir dicha visión radica en el estado actual de la conciencia humana. 
El modo en que nuestro cerebro está estructurado nos predispone hacia una forma de sentir, pensar y actuar en el mundo que ya no es apropiada para los nuevos entornos que hemos creado. 
Es el primer libro que explora cómo la conciencia empática reestructura la forma en que organizamos nuestra vida personal, nos acercamos al conocimiento, perseveramos en ciencia y tecnología, dirigimos el comercio, gobernamos y orquestamos nuestra vida civil. 
El desarrollo de esta conciencia empática es esencial para crear un futuro en que pensemos y nos comportemos de manera que el mundo valga la pena. (Ver)

Jeremi Rifkin: La civilización empática (video)


jueves, 22 de junio de 2017

Mas allá del KOL...Ahora serán los (DOI) Digital Opinion Influencers

Pharma firms have long recognized the power of key opinion leaders (KOLs) in driving influence through traditional channels: journals, speaking events and word of mouth. 
The problem, however, is that healthcare providers (HCPs) and patients are acquiring information about disease and treatment in the online world – and many KOLs are not “digital opinion influencers,” or DOIs. This creates an opportunity – strategic DOI identification, outreach and management – for brand, communications and medical teams that is often overlooked or poorly addressed.


Sizing the opportunity 

This opportunity is largest for pharmaceutical companies providing drugs to address chronic conditions to active patient communities, in which there are high levels of treatment innovation. For example, we recently conducted a study for a pharma client to analyze the healthcare provider DOI community across seven markets for a chronic condition. The results were notable. Of 4,000 HCPs in the community, we identified 1,400 active posters who posted at least three times in the past year. And of these, we identified 131 influencers driving the lion’s share of influence. Interestingly, more than a quarter of these were not traditional KOLs already on the client’s radar. Further, we discovered active posters regularly reached an aggregate audience of approximately 2.8 million followers and fans, many of whom were strategically important prescribers, patient prospects and payer influencers. 

Who are DOIs? 

Digital opinion influencers are influential members of a health community turned to for advice, opinions and information. Their influence flows from reach (followers), their resonance (content sharing) and relevance (topics discussed). Their distinguishing characteristic (versus traditional KOLs) is their use of social media to either create or amplify messages. DOIs are both medical professionals and non-professionals. 

In the medical world, DOIs are typically drawn to social media as a platform for building their reputations. These DOIs share opinions on therapies, discuss presentations from medical congresses and share advice on disease and patient management. 
Another segment — researchers and academics — frequently communicate models of disease understanding based on the latest studies. 
These professional DOIs have converged around Twitter as the preferred channel, particularly around major medical conferences, while simultaneously turning to closed healthcare provider (HCP) platforms for peer-to-peer discussions. (Más)

Ver también:
Pon influencers en tu estrategia de marketing digital

USA: Demandan industrias farmacéuticas por ocultar riesgo de adicción en analgésicos


Attorney General Mike DeWine said the companies created a deadly mess in Ohio that they now need to pay to clean up. 

"This lawsuit is about justice, it's about fairness, it's about what is right," DeWine said in announcing the complaint filed in Ross County, a southern Ohio community slammed by fatal drug overdoses from painkillers and heroin. 

A record 3,050 Ohioans died from drug overdoses in 2015, a figure expected to jump sharply once 2016 figures are tallied.

Ver también:
Demandan en Estados Unidos a farmacéuticas por ocultar riesgo de adicción en analgésicos

DeWine wants an injunction stopping the companies from their alleged misconduct and damages for money the state spent on opiates sold and marketed in Ohio. The attorney general also wants customers repaid for unnecessary opiate prescriptions for chronic pain. 

"These drug companies knew that what they were doing was wrong and they did it anyway," DeWine said. 

 The drugmakers sued by DeWine are Purdue Pharma; Endo Health Solutions; Teva Pharmaceutical Industries, and its subsidiary, Cephalon; Johnson & Johnson and its subsidiary Janssen Pharmaceuticals; and Allergan

They variously manufacture OxyContin, Percocet and a host of other painkillers that DeWine said represent the heart of the problem. (Más)

Ver también:

España: Consumo de opioides sube 83.5%

miércoles, 21 de junio de 2017

Terapias digitales...sleep.io

Salud 2.0: las terapias digitales intentan reducir la fiebre por tomar pastillas 
Algunas 'apps' han demostrado su eficacia para mitigar trastornos como el insomnio sin necesidad de ingerir fármacos. 
La tendencia quiere combinarse o incluso llegar a reemplazar a los tratamientos tradicionales

¿Puede una app reemplazar a una pastilla? Esa es la gran pregunta que gira alrededor de la nueva tendencia conocida como "terapias digitales". La idea se basa en un software capaz de mejorar la salud de una persona de la misma manera que un fármaco, pero sin el mismo coste ni efectos secundarios. 

Las terapias digitales, o "digiterapias" como las llaman algunos, se han convertido en el Santo Grial en algunas partes de Silicon Valley (EEUU), donde los inversores perciben una oportunidad hacer medicina a través de los smartphones. La empresa de capital riesgo Andreessen Horowitz prevé que las terapias digitales se convertirán en la "tercera fase" de la medicina, es decir, serán las sucesoras de los fármacos químicos y basados en proteínas de los que disponemos ahora, pero sin el coste de miles de millones de euros que cuesta llevarlos al mercado. (...)

Para Hames, las terapias digitales se dividen en dos grupos, que él denomina la 

  • "cooperación con medicamentos" y 
  • la "sustitución de medicamentos". 

En su opinión, sleep.io corresponde a la segunda categoría porque realmente elimina la necesidad de somníferos. El responsable añade: "Mediante múltiples estudios revisados por pares hemos sido capaces de demostrar que sus resultados son mejores que los de los fármacos". (Más)

PHARMATON: Nunca te rindas



martes, 20 de junio de 2017

Big Pharma "se autopromociona"

For many years, pharmaceutical companies have spent billions of dollars annually to advertise the benefits of specific drugs. But now, the Pharmaceutical Research and Manufacturers of America (PhRMA) — the leading industry trade group representing brand-name drug companies — has launched a multi-million dollar, multi-year advertising and public relations campaign to promote the overall benefits of the pharmaceutical industry itself. 

The advertising component of this direct-to-consumer campaign, called “GoBoldly,” features national TV, print, digital and radio ads that are intended to highlight recent advances in medicines. PhRMA executives told reporters the campaign would last at least four to five years and cost “high tens of millions of dollars every year.” 

One 90-second TV commercial contains uplifting background music and a mix of captivating images of pharmaceutical researchers in laboratories and patients in hospitals, while scrolling screen text states, “When an indomitable will to cure pushes researchers to find the unfindable and cure the incurable, today’s breakthroughs become tomorrow’s medicines for all of us.

PhRMA’s slick, manipulative advertising campaign represents a desperate but heavily-funded attempt to repair the industry’s well-deserved dismal reputation, given its increasingly outrageous price gouging (not to mention its history of well-documented fraud and other illegal conduct spanning the last 25 years). 

Ver detalles

Public anger over unaffordable drug prices has reached a crescendo following a steady stream of news reports revealing exorbitant monopoly pricing for many new brand-name drugs, as well as overnight price hikes for many older medications. 
A 2016 survey found that 87 percent of U.S. adults are concerned about other people not being able to afford prescription drugs (55 percent are very concerned); 90 percent of seniors shared this concern. Overall, 85 percent of Americans believe that the prices of prescription drugs are too high, and 77 percent think that drug companies are unfairly profiting off of lifesaving drugs. A recent Gallup poll found that no private industry is held in lower esteem by Americans than the pharmaceutical industry.

Many members of Congress, realizing that they can no longer ignore the public outcry over increasingly unaffordable prescription drugs, have begun to take action. For example, some members have introduced legislation that would begin to rein in drug prices (see here and here), while others have initiated investigations into alleged price fixing by some drug companies. And even President Trump asserted shortly before taking office that drug companies are “getting away with murder.” 

PhRMA’s advertising blitz reflects the pharmaceutical industry’s fears that its unfettered ability to charge whatever the market will bear may finally be coming to an end. Don’t be deceived by ads that seek to portray the industry as a knight in shining armor for patients. Call and write to your members of Congress and urge them to stand up for patients, not greedy corporations, by supporting legislation to make medications affordable for all Americans. (Ver)

Mercados: 18 enfermedades olvidadas


Orphan Drugs: Future opportunities and challenges 

The orphan drug sector is booming. Record product approvals, robust pipelines and regulatory incentives. But will the good times last? As the market matures expect increasing competition, clinical research pressures and mounting payer scrutiny. It’s time to plan for the future. 

The Future of Orphan Drug provides a 360-degree scan of the horizon for rare disease therapies. Through primary research with leading industry experts, the report identifies key strategic and tactical pressure points for companies seeking to consolidate or enter this high-growth space. 

 “You will see more companies getting into this space. We will see more novel treatments come out for diseases that never had a treatment. There will be more patient involvement in the process as we go forward.” 
Tom Croce Head of Global Patient Advocacy, Shire

“The role of medical affairs is even more critical and more deep than in these larger indications. Part of it is that you're basically dealing with a disease that might affect a couple of hundred or 1000 patients across the globe. That means you have maybe a dozen of real experts in that field, so there is a much more individual collaboration with these world-class expert centres in a given disease that we need to engage with. It's a much closer relationship in the sense that we continue to support the research in these centres; we continue to support medical education and we continue to support disease awareness, which is very critical.” 
Hartmann Wellhoefer 

“I think a really important thing is the cultivation of creative ways to continuously generate data. The key challenge with an orphan condition is you have a small population. For any drug that comes out, there's lots of questions outstanding - even when it's approved - on long-term safety, real world safety, real world efficacy, efficacy in subpopulations, efficacy in combination with other drugs, efficacy looking at more of these real world endpoints that may or may not have been included in your pivotal trial.” 
Vice President, Head of Medical Affairs, Biotechnology Company 

“[You need to] get people with the right level of skills. You need to have people who can learn quickly where technical expertise is concerned but who are excellent communicators, who are having a good level of soft skills and the mental flexibility to deal with the fast pacing change in our industry. To attract and retain and develop those people will be the key challenge for medical affairs but not just medical affairs in the industry.” 
Michael Zaiac


lunes, 19 de junio de 2017

Humor...es lunes: La homeopatía funciona (?)...


Revelando que no hay un solo dato que demuestre que la homeopatía sea un fraude, un estudio diluido en agua publicado el pasado viernes por la Universidad de Gandía asegura que la homeopatía puede tener fundamentos científicos “especialmente si diluimos los datos hasta que apenas queda rastro detectable de ellos”. 

Si introducimos un artículo científico en un recipiente con agua que ocupe diez veces su volumen original, la homeopatía va ganando efectividad. Y si elevamos esa dilución hasta que cada dato se sumerja en 10.000 partes de agua, apenas podemos distinguir nada en contra”, explica el científico que ha capitaneado el estudio. Según explica, los científicos fueron más allá y llegaron a diluir cada folio del estudio en un factor de 10×60 “hasta que todo era papel mojado”. 

Si se empieza con una solución de 1 mol/L de un dato, la disolución decimal requerida para reducir el número de moléculas a menos de una fórmula por litro es de una parte en 1×1024. Y más allá de ese límite apenas queda nada del artículo científico original y ahí es cuando la homeopatía empieza a mostrarse como realmente efectiva”, afirma el investigador. “¿Qué pone aquí? ¿”Resultados concluyentes” o “resultados inconcluyentes”? No se sabe porque el agua ha corrido toda la tinta”, sentencia. 

Esta semana también se ha sabido que un equipo de científicos hipocondríacos ha logrado descubrir una vacuna para una enfermedad que ni siquiera existe. “Quizá no existe pero yo me la noto”, declaró el jefe del equipo de hipocondríacos. “Creo que la vacuna no ha servido para nada porque me la sigo notando, voy a morir seguro”, aseguró. 

Creatividad (escatológica): Trulance / Synergy Pharmaceuticals

If you’re a responsible user of emojis then you probably opt to include one of them in your texts rather sparingly. The smiling, bright-eyed pile of poop—one of the most popular among the 2,000 emojis available—is a statement piece that tends to be reserved for special occasions. It can be used in place of the common expletive, insinuate that things have gone in the metaphorical toilet or evoke passive-aggression. The poop emoji is also employed by some to articulate physical health, typically interpreted as “I feel like crap.” 

Recently, big pharma caught drift of this last one. In honor of Digestive Disease Week and to promote it’s new drug (Trulance) to treat chronic idiopathic constipation, Synergy Pharmaceuticals has unveiled the Poop Troop. The phone app, available to both iPhone and Android users, is a keyboard of highly nuanced poop emojis that provide cute animated visuals of the myriad shapes and consistencies of human feces. To evoke the problem of irregularity there’s Stressed Out Stooly, Clogged Chris, Plugged Up Paulie and Left-Out Lumpy. One the other end of the spectrum one will find the company of Waterworks Willy, Runny Ron, Diarrhea Dave and Squirt. Of course, the guys we all want to get to know are the ones that symbolize regular bowel movements, which include Sausage Sally, Splasher Asher, Ploptastic Peter, Mr. Smooth and Miss La Poop. (Ver)

Ver también: 
El 'emoji' de la caca, estrella de una campaña de salud

domingo, 18 de junio de 2017

Mañana me encontrareis en...Seminario de Actualización en Investigación Clínica

Seminario de actualización en investigación de la Medicina Personalizada de Precisión (MPP) para medios de comunicación. 

Perspectivas de futuro en la investigación clínica 

La Asociación Nacional de Informadores de la Salud (ANIS) y la Fundación Instituto Roche (FIR) colaboran para organizar un Seminario de Actualización en Investigación de la Medicina Personalizada de Precisión (MPP) para medios de comunicación. 

Una de las principales labores de los periodistas y comunicadores científicos es trasladar a la sociedad los resultados de la investigación clínica de manera rigurosa y entendible; por este motivo uno de los objetivos de este seminario es abordar los conceptos y la terminología claves acerca de los ensayos clínicos. 
Las noticias médicas representan casi la mitad de toda la información científica que aparece en la prensa generalista y especializada, teniendo un gran impacto en la sociedad. Durante el seminario se abordarán conceptos sobre la investigación, los estudios clínicos y la interpretación de los artículos científicos. 

El seminario se celebrará el próximo 19 de junio en el salón de actos de la Asociación de la Prensa de Madrid y las inscripciones se realizarán a través de la Secretaría Técnica de ANIS.